Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study

Area of Science:

• Nephrology
• Oncology
• Genetics

Background:

• Renal-related disease is a leading cause of death in adults with Tuberous Sclerosis Complex (TSC).
• Renal angiomyolipomas in TSC can cause chronic kidney disease (CKD) and hemorrhage.
• Current guidelines recommend mTOR inhibitors for growing angiomyolipomas over 3 cm.

Purpose of the Study:

• To review outcomes data for renal angiomyolipoma management.
• To present recent data on sirolimus and everolimus for angiomyolipoma treatment.
• To propose earlier initiation of mTOR inhibitor therapy for TSC-associated renal angiomyolipomas.

Main Methods:

• Review of patient outcome data for guideline development.
• Analysis of recent clinical data for sirolimus and everolimus efficacy and safety.
• Hypothesis formulation for mTORC1 haploinsufficiency in TSC-related CKD.

Main Results:

• Sirolimus and everolimus effectively reduce angiomyolipoma volume with acceptable safety.
• Long-term mTOR inhibitor therapy demonstrates preservation of renal function.
• Angiomyolipomas can recur after embolization, highlighting the need for systemic therapy.

Conclusions:

• mTOR inhibitors offer a systemic approach targeting TSC pathophysiology for multiple manifestations.
• Earlier mTOR inhibitor therapy for renal angiomyolipomas may prevent severe complications and reduce mortality.
• Consideration of new guidelines supporting earlier mTOR inhibitor initiation is warranted.